Stockpolly
Search
KYNB · NASDAQ · Biotechnology

Kyntra Bio (KYNB)

Develops CD46-targeted cancer therapies and roxadustat for anemia in lower-risk myelodysplastic syndromes.

$8.57
Pre-market−0.01 (−0.12%)
At close$8.58(+7.92%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue402725146−12331114−1
Cost of revenue4558335−21100040
Gross profit3622−32−3241−10321120−1
9976171558−1117136161316
Research & development61523632221961787
26240018−13875869
General & administrative000000000009
Other expenses130−20−17191000100
Operating income−63−54−49−46−17−92−15−12−5−14−14−18
0−20−104−2−2−8−1−130
Interest income422140001310
Interest expense552250222222
Other non-operating income−4−2−2−1−400067−132
Income before tax−64−56−49−47−17−88−17−14−13−15−1512
Income tax expense000000000000
Net income from continuing operations−64−56−49−47−17−88−17−14−13−15−1512
Discontinued operations001632002161625300
Other adjustments00000106000000
Net income−64−56−33−16−17185−814838−1512
EPS, basic−$0.65−$0.57−$0.33−$3.89−$4.25$4.50$0.05−$1.88$49.61$9.38−$3.76$2.96
EPS, diluted−$0.65−$0.57−$0.33−$3.89−$4.25$4.50$0.05−$1.88$49.61$9.38−$3.76$2.96
Weighted average shares, basic9844444444444
Weighted average shares, diluted9844444444444
EBITDA−57−50−46−45−12−91−14−12−11−21−13−49
Depreciation & amortization221110000000
EBIT−59−52−47−46−13−91−15−12−11−21−13−49